Plasma TDP-43 is a potential biomarker for advanced limbic-predominant age-related TDP-43 encephalopathy neuropathologic change [0.03%]
血浆TDP-43是潜在的额颞叶痴呆和行为变异型阿尔茨海默病脑内变性改变生物标志物
Jijing Wang,Julie A Schneider,David A Bennett et al.
Jijing Wang et al.
M102 activates both NRF2 and HSF1 transcription factor pathways and is neuroprotective in cell and animal models of amyotrophic lateral sclerosis [0.03%]
M102激活NRF2和HSF1转录因子途径并在细胞及动物模型中对渐冻症具有神经保护作用
Amy F Keerie,Raquel Rua Martins,Chloe F Allen et al.
Amy F Keerie et al.
M102 is a central nervous system (CNS) penetrant small molecule electrophile which activates in vivo the NF-E2 p45-related factor 2-antioxidant response element (NRF2-ARE) pathway, as well as transcription of heat-shock element (HSE) associ...
Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies [0.03%]
路易体痴呆的神经病理学：路易相关病变，α-突触核蛋白寡聚体和共病病理
Hiroaki Sekiya,Tomoyasu Matsubara,Michael A DeTure et al.
Hiroaki Sekiya et al.
Lewy body dementia is the second most common form of neurodegenerative dementia, following Alzheimer's disease. This umbrella term encompasses dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). The distinction between t...
C-terminus-dependent detection of lysosomal alpha-synuclein in nigral Parkinson's disease human brain neurons [0.03%]
基于C端的黑质帕金森病人类脑神经元溶酶体α-突触核蛋白检测
Martino L Morella,Bana Al Khayrat,Tim E Moors et al.
Martino L Morella et al.
The abnormal accumulation of alpha-Synuclein (αSyn) within neurons is a hallmark of synucleinopathies, such as Parkinson's disease (PD), and could stem from impaired protein degradation. Genetic, in vitro, and post-mortem studies have sugg...
Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer's disease [0.03%]
星形胶质细胞活化与APOE ε4基因型在阿尔茨海默病中相互作用可加速pTau相关的tau病理变化
Xiaoxie Mao,Yan Wang,Ying Luan et al.
Xiaoxie Mao et al.
Background: Various plasma phosphorylated tau species have been shown to be associated with amyloid-β (Aβ) PET and Tau PET in Alzheimer’s disease (AD), but whether APOE ε4 affects the interaction between glial fibrill...
Claire E Young,Melanie A Samuel
Claire E Young
Microglia are the resident immune cell of the brain, and alterations in microglia signaling have been implicated in many neurodegenerative disorders. While microglia responses to central cues and other brain cell types are well documented, ...
Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology [0.03%]
O-连接的N-乙酰氨基葡萄糖（O-GlcNAc）周转的调节影响α-突触核蛋白的放大、降解和相关的神经炎症病理变化
Yongzhen Miao,Ting Zhang,Zhuoya Ma et al.
Yongzhen Miao et al.
Background: The accumulation and propagation of α-synuclein (α-syn) are hallmark features of Parkinson's disease (PD) and related neurodegenerative disorders. O-GlcNAcylation, an abundant post-translational modification...
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies [0.03%]
糖尿病药物在阿尔茨海默病中的作用：一项系统性前临床和临床研究综述
Miriam Corraliza-Gomez,Maria Vargas-Soria,Monica Garcia-Alloza
Miriam Corraliza-Gomez
The potential neuroprotective effects of antidiabetic treatments have been largely assessed in Alzheimer's disease (AD) and AD-like dementia models, with or without metabolic disorders. In this Line, these effects Have also been addressed i...
Entering the era of precision medicine to treat amyotrophic lateral sclerosis [0.03%]
步入精准医疗时代以治疗肌萎缩侧索硬化症
Frances Theunissen,Loren Flynn,Alfredo Iacoangeli et al.
Frances Theunissen et al.
With the disease modifying therapy Qalsody (tofersen) which targets the RNA product of the SOD1 gene, having been shown effective in amyotrophic lateral sclerosis (ALS), the present perspective seeks to explore progress towards the implemen...
Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease [0.03%]
Vutiglabridin作为帕金森病临床前模型中Paraoxonase-2调节剂的神经治疗作用
Heeyoung An,Sora Kang,Jaejin Shin et al.
Heeyoung An et al.
Background: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease characterized by motor impairment resulting from the degeneration of dopaminergic neurons in the substantia nigra, alongside α -...